


Fasudil Hydrochloride

Cat. No.:	HY-10341		
CAS No.:	105628-07-7		
Molecular Formula:	C ₁₄ H ₁₈ ClN ₃ O ₂ S		
Molecular Weight:	327.83		
Target:	ROCK; Calcium Channel; Autophagy; PKA; PKC		
Pathway:	Cell Cycle/DNA Damage; Stem Cell/Wnt; TGF-beta/Smad; Membrane Transporter/Ion Channel; Neuronal Signaling; Autophagy; Protein Tyrosine Kinase/RTK; Epigenetics		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

H₂O : 55 mg/mL (167.77 mM; Need ultrasonic)

DMSO : ≥ 31 mg/mL (94.56 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.0504 mL	15.2518 mL	30.5036 mL
	5 mM	0.6101 mL	3.0504 mL	6.1007 mL
	10 mM	0.3050 mL	1.5252 mL	3.0504 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Fasudil Hydrochloride (HA-1077 Hydrochloride; AT877 Hydrochloride), is a nonspecific ROCK inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively^[1]. Fasudil Hydrochloride is also a potent Ca²⁺ channel antagonist and vasodilator^[2].

IC₅₀ & Target

p160ROCK 0.33 μM (K _i)	ROCK2 0.158 μM (IC ₅₀)	PKA 4.58 μM (IC ₅₀)	PKC 12.30 μM (IC ₅₀)
PKG 1.65 μM (IC ₅₀)			

In Vitro	<p>Fasudil Hydrochloride (100 μM) inhibits cell spreading, the formation of stress fibers, and expression of α-SMA with concomitant suppression of cell growth in rat HSCs and human HSC-derived TWNT-4 cells^[4].</p> <p>Fasudil Hydrochloride (50-100 μM; 24 hours) inhibits the LPA-induced phosphorylation of ERK1/2, JNK, and p38 detected by western blotting in rat HSCs and human HSC-derived TWNT-4 cells^[4].</p> <p>Fasudil Hydrochloride (25-100 μM; 24 hours) suppresses transcription of collagen and TIMP, stimulates transcription of MMP-1 in human HSC-derived TWNT-4 cells^[4].</p> <p>Western Blot Analysis^[4]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Rat HSCs and human HSC-derived TWNT-4 cells</td> </tr> <tr> <td>Concentration:</td> <td>50 μM; 100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Suppressed the LPA-induced phosphorylation of ERK1/2, JNK and p38 MAPK by 60%, 70%, and 90%, respectively.</td> </tr> </table> <p>RT-PCR^[4]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Rat HSCs and human HSC-derived TWNT-4 cells</td> </tr> <tr> <td>Concentration:</td> <td>25 μM; 50 μM; 100 μM 24 hours</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Reduced the expression of type I collagen, α-SMA, and TIMP-1.</td> </tr> </table>	Cell Line:	Rat HSCs and human HSC-derived TWNT-4 cells	Concentration:	50 μ M; 100 μ M	Incubation Time:	24 hours	Result:	Suppressed the LPA-induced phosphorylation of ERK1/2, JNK and p38 MAPK by 60%, 70%, and 90%, respectively.	Cell Line:	Rat HSCs and human HSC-derived TWNT-4 cells	Concentration:	25 μ M; 50 μ M; 100 μ M 24 hours	Incubation Time:	24 hours	Result:	Reduced the expression of type I collagen, α -SMA, and TIMP-1.
	Cell Line:	Rat HSCs and human HSC-derived TWNT-4 cells															
Concentration:	50 μ M; 100 μ M																
Incubation Time:	24 hours																
Result:	Suppressed the LPA-induced phosphorylation of ERK1/2, JNK and p38 MAPK by 60%, 70%, and 90%, respectively.																
Cell Line:	Rat HSCs and human HSC-derived TWNT-4 cells																
Concentration:	25 μ M; 50 μ M; 100 μ M 24 hours																
Incubation Time:	24 hours																
Result:	Reduced the expression of type I collagen, α -SMA, and TIMP-1.																
In Vivo	<p>Fasudil (30 μg) increases CBF by 50% via intra-coronary injection to dogs. Fasudil (0.01, 0.03, 0.1 and 0.3 mg/kg, bolus, i.v.) decreases MBP and increases HR, VBF, CBF, RBF, and FBF. Fasudil (1.0 ng/mL) increases cardiac output. Fasudil via i.v. produces a significant fall in MBP, left ventricular systolic pressure and total peripheral resistance with an increase in HR and cardiac output, but without obvious effect on right atrial pressure, dP/dt or left ventricular minute work in dogs^[3]. Fasudil exhibits protectable effects on cardiovascular disease and reduces the activation of JNK and attenuates mitochondrial-nuclear translocation of AIF under ischemic injury^[6]. Fasudil (100 mg/kg/day, p.o.) significantly reduces incidence and mean maximum clinical score of EAE in SJL/J mice immunized with PLP p139-151. Fasudil inhibits the proliferative response of splenocytes to the antigen in mice. Fasudil decreases inflammation, demyelination, axonal loss and APP positive in spinal cord of Fasudil-treated mice via p.o. administration^[7].</p>																

CUSTOMER VALIDATION

- *Sci Transl Med.* 2018 Jul 18;10(450). pii: eaaq1093.
- *Sci Rep.* 2018 Feb 6;8(1):2477.
- *Adipocyte.* 2019 Dec;8(1):114-124.
- *Biomed Rep.* 2015 May;3(3):361-364.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Chen M, et al. Fasudil and its analogs: a new powerful weapon in the long war against central nervous system disorders? *Expert Opin Investig Drugs.* 2013 Apr;22(4):537-50.

-
- [2]. Huang XN, et al. The effects of fasudil on the permeability of the rat blood-brain barrier and blood-spinal cord barrier following experimental autoimmune encephalomyelitis. *J Neuroimmunol.* 2011 Oct 28;239(1-2):61-7.
- [3]. Uehata M, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. *Nature.* 1997 Oct 30;389(6654):990-4.
- [4]. Fukushima M, et al. Fasudil hydrochloride hydrate, a Rho-kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells. *Liver Int.* 2005 Aug;25(4):829-38.
- [5]. Corbin KD, et al. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. *Curr Opin Gastroenterol.* 2012 Mar;28(2):159-65.
- [6]. Zhang J, et al. Inhibition of the activity of Rho-kinase reduces cardiomyocyte apoptosis in heart ischemia/reperfusion via suppressing JNK-mediated AIF translocation. *Clin Chim Acta.* 2009 Mar;401(1-2):76-80.
- [7]. Sun X, et al. The selective Rho-kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis. *J Neuroimmunol.* 2006 Nov;180(1-2):126-34. Epub 2006 Sep 22.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA